© 2019 Kibler et al.As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (previously described) designed to improve on the results of the RV144 phase III clinical trial. The construct, NYVAC-KC, is a replication-competent, attenuated recombinant of the vaccinia virus strain NYVAC. NYVAC is a vector that has been used in many previous clinical studies but is replication deficient. Here, we report a side-by-side comparison of replication-restricted NYVAC and replication-competent NYVAC-KC in a nonhuman primate study, which utilized a prime-boost regimen similar to that of RV144. NYVAC-C and NYVAC-C-KC express the HIV-1 antigens gp140, and Gag/Gag-Pol-Nef-derived virus-like particles (VLP...
Attenuated poxviruses are safe and capable of expressing foreign antigens. Poxviruses are applied in...
Multiple approaches utilizing viral and DNA vectors have shown promise in the development of an effe...
The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen c...
As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccin...
Background: In order to improve the immunogenicity of currently available non-replicating pox virus ...
While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial (RV144) h...
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Ga...
abstract: While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial...
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Ga...
UNLABELLED: We compared the HIV-1-specific cellular and humoral immune responses elicited in rhesus ...
UNLABELLED: In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HI...
Background: To enhance the induction of insert specific immune responses, a new generation of replic...
abstract: Attenuated poxviruses are safe and capable of expressing foreign antigens. Poxviruses are ...
In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine fi...
Attenuated poxviruses are safe and capable of expressing foreign antigens. Poxviruses are applied i...
Attenuated poxviruses are safe and capable of expressing foreign antigens. Poxviruses are applied in...
Multiple approaches utilizing viral and DNA vectors have shown promise in the development of an effe...
The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen c...
As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccin...
Background: In order to improve the immunogenicity of currently available non-replicating pox virus ...
While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial (RV144) h...
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Ga...
abstract: While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial...
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Ga...
UNLABELLED: We compared the HIV-1-specific cellular and humoral immune responses elicited in rhesus ...
UNLABELLED: In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HI...
Background: To enhance the induction of insert specific immune responses, a new generation of replic...
abstract: Attenuated poxviruses are safe and capable of expressing foreign antigens. Poxviruses are ...
In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine fi...
Attenuated poxviruses are safe and capable of expressing foreign antigens. Poxviruses are applied i...
Attenuated poxviruses are safe and capable of expressing foreign antigens. Poxviruses are applied in...
Multiple approaches utilizing viral and DNA vectors have shown promise in the development of an effe...
The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen c...